» Articles » PMID: 34922004

The Soluble Epoxide Hydrolase Inhibitor GSK2256294 Decreases the Proportion of Adipose Pro-inflammatory T Cells

Abstract

Adipose tissue contains a complex immune environment and is a central contributor to heightened systemic inflammation in obese persons. Epoxyeicosatrienoic acids (EETs) are lipid signaling molecules that decrease inflammation in obese animals, but their effect on inflammation in humans is unknown. The enzyme soluble epoxide hydrolase (sEH) hydrolyzes EETs to less active diols, and we hypothesized that pharmacologic sEH inhibition would decrease adipose inflammation in obese individuals. We treated obese prediabetic adults with the sEH inhibitor GSK2256294 versus placebo in a crossover design, collected subcutaneous abdominal adipose tissue via lipoaspiration and characterized the tissue T cell profile. Treatment with GSK2256294 decreased the percentage of pro-inflammatory T cells producing interferon-gamma (IFNγ), but not interleukin (IL)-17A, and decreased the amount of secreted tumor necrosis factor-alpha (TNFα). Understanding the contribution of the EET/sEH pathway to inflammation in obesity could lead to new strategies to modulate adipose and systemic inflammation.

Citing Articles

Encoding and display technologies for combinatorial libraries in drug discovery: The coming of age from biology to therapy.

Fan Y, Feng R, Zhang X, Wang Z, Xiong F, Zhang S Acta Pharm Sin B. 2024; 14(8):3362-3384.

PMID: 39220863 PMC: 11365444. DOI: 10.1016/j.apsb.2024.04.006.


Soluble epoxide hydrolase inhibitors for smoking-associated inflammatory lung diseases and chronic obstructive pulmonary disease: a meta-analytical systematic review of preclinical and clinical studies.

Felipe A, Miguel C, Bernardes A, Perissinotto R, Trindade-da-Silva C, Martins-de-Abreu M Am J Transl Res. 2023; 15(11):6649-6659.

PMID: 38074809 PMC: 10703658.

References
1.
Saltiel A, Olefsky J . Inflammatory mechanisms linking obesity and metabolic disease. J Clin Invest. 2017; 127(1):1-4. PMC: 5199709. DOI: 10.1172/JCI92035. View

2.
Russo L, Lumeng C . Properties and functions of adipose tissue macrophages in obesity. Immunology. 2018; 155(4):407-417. PMC: 6230999. DOI: 10.1111/imm.13002. View

3.
Neeland I, Poirier P, Despres J . Cardiovascular and Metabolic Heterogeneity of Obesity: Clinical Challenges and Implications for Management. Circulation. 2018; 137(13):1391-1406. PMC: 5875734. DOI: 10.1161/CIRCULATIONAHA.117.029617. View

4.
Golia E, Limongelli G, Natale F, Fimiani F, Maddaloni V, Pariggiano I . Inflammation and cardiovascular disease: from pathogenesis to therapeutic target. Curr Atheroscler Rep. 2014; 16(9):435. DOI: 10.1007/s11883-014-0435-z. View

5.
Luther J, Brown N . Epoxyeicosatrienoic acids and glucose homeostasis in mice and men. Prostaglandins Other Lipid Mediat. 2016; 125:2-7. PMC: 5035218. DOI: 10.1016/j.prostaglandins.2016.07.010. View